The biopharma flotation remains a rare beast

For the second quarter running only three drug developers floated on Western stock exchanges, as the biotech bear market continued to squash demand for new offerings. And the stats get worse: the total sum raised plunged once again, with only $153m banked in the third quarter, Evaluate Vantage finds.